Epithelial ovarian cancer: Difference between revisions
Jump to navigation
Jump to search
Hannan Javed (talk | contribs) No edit summary |
Hannan Javed (talk | contribs) No edit summary |
||
Line 57: | Line 57: | ||
* Decreased anoikis | * Decreased anoikis | ||
|- | |- | ||
|Insulin-like growth factor/receptor ILGF/ILGFR<ref name="pmid11577173">{{cite journal |vauthors=Laron Z |title=Insulin-like growth factor 1 (IGF-1): a growth hormone |journal=MP, Mol. Pathol. |volume=54 |issue=5 |pages=311–6 |date=October 2001 |pmid=11577173 |pmc=1187088 |doi= |url=}}</ref><ref name="pmid22682634">{{cite journal |vauthors=Weroha SJ, Haluska P |title=The insulin-like growth factor system in cancer |journal=Endocrinol. Metab. Clin. North Am. |volume=41 |issue=2 |pages=335–50, vi |date=June 2012 |pmid=22682634 |pmc=3614012 |doi=10.1016/j.ecl.2012.04.014 |url=}}</ref> | |Insulin-like growth factor/receptor ILGF/ILGFR<ref name="pmid11577173">{{cite journal |vauthors=Laron Z |title=Insulin-like growth factor 1 (IGF-1): a growth hormone |journal=MP, Mol. Pathol. |volume=54 |issue=5 |pages=311–6 |date=October 2001 |pmid=11577173 |pmc=1187088 |doi= |url=}}</ref><ref name="pmid22682634">{{cite journal |vauthors=Weroha SJ, Haluska P |title=The insulin-like growth factor system in cancer |journal=Endocrinol. Metab. Clin. North Am. |volume=41 |issue=2 |pages=335–50, vi |date=June 2012 |pmid=22682634 |pmc=3614012 |doi=10.1016/j.ecl.2012.04.014 |url=}}</ref><ref name="pmid12237896">{{cite journal |vauthors=Lukanova A, Lundin E, Toniolo P, Micheli A, Akhmedkhanov A, Rinaldi S, Muti P, Lenner P, Biessy C, Krogh V, Zeleniuch-Jacquotte A, Berrino F, Hallmans G, Riboli E, Kaaks R |title=Circulating levels of insulin-like growth factor-I and risk of ovarian cancer |journal=Int. J. Cancer |volume=101 |issue=6 |pages=549–54 |date=October 2002 |pmid=12237896 |doi=10.1002/ijc.10613 |url=}}</ref> | ||
| | | | ||
* Promotes growth | * Promotes growth |
Revision as of 16:01, 26 February 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Hannan Javed, M.D.[2]
Possible genetic alteration in epithelial ovarian cancers | ||
---|---|---|
Protein | Normal function | Result of mutation |
Epidermal growth factor receptor (HER-1)[1][2] |
|
|
Human Epidermal Growth Factor Receptor 2 (HER-2)[1][2] |
|
|
Non-receptor tyrosine kinase Src[3][4] | Involved in regulation of
|
|
CSF-1/fms[5][6][7] |
|
|
Insulin-like growth factor/receptor ILGF/ILGFR[8][9][10] |
|
|
k-ras | ||
b-raf | ||
TGF-β | ||
myc | ||
Cyclin D/Cdk4/6 | ||
Cyclin E/Cdk2 | ||
Cyclin B/Cdk1 | ||
p16 | ||
p27 (kip-1) | ||
p21 (WAF-1) | ||
NFκB | ||
NOEY(ARHI) | ||
PIP3/Akt | ||
PTEN | ||
p53 | ||
BRCA1 | ||
BRCA2 | ||
MLH1/MSH2 | ||
Fas ligand | ||
HLA-G | ||
hTERT | ||
VEGF/VEGFR | ||
IL-8 | ||
EphA2 | ||
MMPs | ||
αvβ3 | ||
FAK | ||
E-cadherin | ||
References
- ↑ 1.0 1.1 Wee P, Wang Z (May 2017). "Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways". Cancers (Basel). 9 (5). doi:10.3390/cancers9050052. PMC 5447962. PMID 28513565.
- ↑ 2.0 2.1 Iqbal N, Iqbal N (2014). "Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications". Mol Biol Int. 2014: 852748. doi:10.1155/2014/852748. PMC 4170925. PMID 25276427.
- ↑ Zan L, Wu H, Jiang J, Zhao S, Song Y, Teng G, Li H, Jia Y, Zhou M, Zhang X, Qi J, Wang J (July 2011). "Temporal profile of Src, SSeCKS, and angiogenic factors after focal cerebral ischemia: correlations with angiogenesis and cerebral edema". Neurochem. Int. 58 (8): 872–9. doi:10.1016/j.neuint.2011.02.014. PMC 3100427. PMID 21334414.
- ↑ Reinecke JB, Katafiasz D, Naslavsky N, Caplan S (April 2014). "Regulation of Src trafficking and activation by the endocytic regulatory proteins MICAL-L1 and EHD1". J. Cell. Sci. 127 (Pt 8): 1684–98. doi:10.1242/jcs.133892. PMC 3986674. PMID 24481818.
- ↑ Saad AF, Hu W, Sood AK (December 2010). "Microenvironment and pathogenesis of epithelial ovarian cancer". Horm Cancer. 1 (6): 277–90. doi:10.1007/s12672-010-0054-2. PMC 3199131. PMID 21761359.
- ↑ Dwyer AR, Greenland EL, Pixley FJ (June 2017). "Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling". Cancers (Basel). 9 (6). doi:10.3390/cancers9060068. PMC 5483887. PMID 28629162.
- ↑ Abraham D, Zins K, Sioud M, Lucas T, Schäfer R, Stanley ER, Aharinejad S (March 2010). "Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma". Int. J. Cancer. 126 (6): 1339–52. doi:10.1002/ijc.24859. PMC 3222589. PMID 19711348.
- ↑ Laron Z (October 2001). "Insulin-like growth factor 1 (IGF-1): a growth hormone". MP, Mol. Pathol. 54 (5): 311–6. PMC 1187088. PMID 11577173.
- ↑ Weroha SJ, Haluska P (June 2012). "The insulin-like growth factor system in cancer". Endocrinol. Metab. Clin. North Am. 41 (2): 335–50, vi. doi:10.1016/j.ecl.2012.04.014. PMC 3614012. PMID 22682634.
- ↑ Lukanova A, Lundin E, Toniolo P, Micheli A, Akhmedkhanov A, Rinaldi S, Muti P, Lenner P, Biessy C, Krogh V, Zeleniuch-Jacquotte A, Berrino F, Hallmans G, Riboli E, Kaaks R (October 2002). "Circulating levels of insulin-like growth factor-I and risk of ovarian cancer". Int. J. Cancer. 101 (6): 549–54. doi:10.1002/ijc.10613. PMID 12237896.